Latest News
& Press Releases

Sarepta Therapeutics and Alnylam Pharmaceuticals have announced the pricing of $1 billion and $900 million in convertible senior notes respectively.

Pres. Joe Biden vowed to bolster the U.S. biotechnology sector after signing an executive order to improve the fight against cancer.

Akero Therapeutics announced its mid-stage drug candidate, efruxifermin improved liver fibrosis and prevented disease worsening in patients with NASH.

There is no one-size-fits-all algorithm for AI that enables drug developers to quickly identify the features they seek. Instead, researchers are selecting best-of-breed algorithms for customized analytics.

Scientists from the Francis Crick Institute and University College London say they have, for the first time, conclusively explained how air pollution leads to lung cancer in nonsmokers.

Novartis has had a busy few days, announcing plans to shutter a Sandoz plant, a $300 million infrastructure investment, and Cosentyx, Kisqali and Tislelizumab readouts.

AstraZeneca presented data showing Imfinzi and Tagrisso boosted survival chances for patients in different forms of lung cancer at ESMO on Monday.

President Joe Biden tapped Ginkgo Bioworks veteran Renee Wegrzyn to helm the recently-established Advanced Research Projects Agency for Health (ARPA-H).

It was a busy weekend at ESMO 2022 with Merck, Astellas, Seagen, Regeneron, AstraZeneca and GRAIL all presenting data from their various cancer programs.

Young oncologists arguably stand to gain the most at ESMO by having the opportunity to discuss industry news and network with the most experienced doctors and professionals in their field.

Pretzel Therapeutics launched Monday with $72.5 million in Series A financing to develop novel, mitochondria-based therapies to treat rare genetic disorders and diseases of aging.

Regeneron’s oncology strategy is centered around improving checkpoint inhibitor treatments with combination therapies, according to a pipeline overview presented Monday morning.

Expanded sweetener molecule development program aims to broaden access to plant-based sweetening solutions tailored to diverse customer food and beverage categories.

• $5.5 million financing that closed on April 2, 2026 together with $5.7 million in capital raised in Q1-2026, expected to provide Company with cash runway into 2027 • $4.5 million of accrued VAT refunds and R&D refundable tax credits from UK subsidiary begin maturing, including $1.9 million VAT cash refund expected in June 2026 • Successful EMA and Australia TGA (ATGA) meetings aligned around use of existing biomarker and pending release of 3-year overall survival data to support Conditional Marketing Authorisations (CMAs) for OST-HER2 in prevention or delay of recurrence in fully-resected, pulmonary metastatic osteosarcoma (“Metastatic Osteosarcoma”) • 2.5-year overall survival data expected to be released during ASCO 2026 • EMA and ATGA have aligned on key design aspects of confirmatory Phase 3 Metastatic Osteosarcoma protocol required to have commenced prior to grant of CMAs or FDA BLA, including alignment on 3-year overall survival as a primary clinical efficacy endpoint • Upcoming U.S. FDA Type C meeting and U.K. MHRA SAM meeting to align with EMA & ATGA prior to Australia Clinical Trial Notification submission for Phase 3, including alignment on 3-year overall survival as a primary clinical efficacy endpoint. U.S. FDA (“FDA”) Pre-BLA meeting to confirm alignment on surrogate and primary clinical efficacy endpoints with EMA/ATGA, including alignment on 3-year overall survival as a primary clinical efficacy endpoint, and seek decisions on rolling review acceptance and RMAT designation following the EMA and U.K. MHRA granting ATMP designation (EMA/MHRA RMAT equivalent) for OST-HER2 in Metastatic Osteosarcoma • OS Animal Health S-1 filing for proposed ‘Go-Public’ transaction and receipt of SEC comments